RIPK1 and eosinophilia-myalgia syndrome: Our results demonstrated that CUR exhibits high binding affinity to Fas/RIPK1 in silico and effectively attenuates EMs progression by targeting this pathway, offering new mechanistic insights for EMs therapeutics.